The drug being tested in this study is GSK1223249. The drug works by inhibiting a protein
that prevents nerve growth.
The trial is expected to involve approximately 36 patients. The study objective is to
investigate the tolerability, safety and the way the body handles GSK1223249 after a range of
single doses in patients with Multiple Sclerosis (MS).